Cellectar Biosciences, Inc. (CLRB) Stock Forecast
Data as of May 10, 2026Healthcare · Current price $3.10 (-6.06%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
CLRB vs Sector & Market
| Metric | CLRB | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 1 | 8 | 19 |
| Target Upside | +254.8% | +1710.7% | +16.4% |
| P/E Ratio | -0.50 | 3.30 | 27.60 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $4M | $4M | $4M | 3 |
| 2027-12-31 | $10M | $10M | $10M | 3 |
| 2028-12-31 | $46M | $46M | $46M | 3 |
| 2029-12-31 | $99M | $99M | $99M | 2 |
| 2030-12-31 | $152M | $152M | $152M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-5.31 | $-3.98 | $-2.65 | 2 |
| 2027-12-31 | $-3.04 | $-3.04 | $-3.04 | 2 |
| 2028-12-31 | $-1.33 | $-1.01 | $-0.53 | 3 |
| 2029-12-31 | $1.17 | $1.17 | $1.17 | 1 |
| 2030-12-31 | $2.04 | $2.04 | $2.04 | 1 |
Frequently Asked Questions
What is the analyst consensus for CLRB?
The consensus among 1 analysts covering Cellectar Biosciences, Inc. (CLRB) is Buy with an average price target of $12.00.
What is the highest price target for CLRB?
The highest analyst price target for CLRB is $12.00.
What is the lowest price target for CLRB?
The lowest analyst price target for CLRB is $12.00.
How many analysts cover CLRB?
1 analysts have issued ratings for Cellectar Biosciences, Inc. in the past 12 months.
Is CLRB a buy or sell right now?
Based on 1 analyst ratings, CLRB has a consensus rating of Buy (2.00/5) with a +254.8% upside to the consensus target of $12.00.
What are the earnings estimates for CLRB?
Analysts estimate CLRB will report EPS of $-3.98 for the period ending 2026-12-31, with revenue estimated at $4M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.